Extracorporeal Shock Wave Therapy for Coronary Artery Disease: Relationship of Symptom Amelioration and Ischemia Improvement

Authors

  • Akira Yamada Department of Cardiology, Fujita Health University School of Medicine
  • Hideki Kawai Department of Cardiology, Fujita Health University School of Medicine
  • Kayoko Takada Department of Cardiology, Fujita Health University School of Medicine
  • Kenji Shiino Department of Cardiology, Fujita Health University School of Medicine
  • Masayoshi Sarai Department of Cardiology, Fujita Health University School of Medicine
  • Meiko Miyagi Department of Cardiology, Fujita Health University School of Medicine
  • Sadako Motoyama Department of Cardiology, Fujita Health University School of Medicine
  • Youko Takakuwa Department of Cardiology, Fujita Health University School of Medicine, 1-98 Dengakugakubo Kutsukake-cho Toyoake, Japan
  • Yukio Ozaki Department of Cardiology, Fujita Health University School of Medicine
Abstract:

Objective(s): The current management of coronary artery disease (CAD) relies on three major therapeutic options, namely medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). However, severe CAD that is not indicated for PCI or CABG still bears a poor prognosis due to the lack of effective treatments. In 2006, extracorporeal cardiac shock wave (SW) therapy reported on human for the first time. This treatment resulted in better myocardial perfusion as evaluated by dipyridamole stress thallium scintigraphy, angina symptoms, and exercise tolerance. The aim of the present study was to investigate myocardial perfusion images and evaluate the relationship between the ischemia improvement and symptom amelioration by SW therapy. Methods: We treated ten patients (i.e., nine males and one female) with cardiac SW therapy who had CAD but not indicated for PCI or CABG and aged 63–89 years old. After the SW therapy, all patients were followed up for three months to evaluate any amelioration of the myocardial ischemia based on symptoms, adenosine stress thallium scintigraphy, transthoracic echocardiography, and blood biochemical examinations. Results: The changes in various parameters were evaluated before and after cardiac SW therapy. The cardiac SW therapy resulted in a significant improvement in the symptoms as evaluated by the Canadian Cardiovascular Society [CCS] class score (P=0.016) and a tendency to improve in summed stress score (SSS) (P=0.068). However, no significant improvement was observed in the summed rest score (SRS), summed difference score (SDS), left ventricular wall motion score index (LVWMSI), N-terminal pro-brain natriuretic, and troponin I. The difference of CCS class score (ΔCCS) was significantly correlated with those of SSS (ΔSSS) and SDS (ΔSDS) (r=0.69, P=0.028 and r=0.70, P=0.025, respectively). There was no significant correlation between ΔCCS and other parameters. Furthermore, no significant difference was observed between the CCS improved and non-improved groups in terms of the baseline characteristics. Conclusion: The current study demonstrated the potential efficacy and safety of Cardiac SW therapy in CAD patients. As the findings indicated, symptom amelioration was associated with ischemia improvement by extracorporeal shock wave therapy for the CAD patients.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

A modified regimen of extracorporeal cardiac shock wave therapy for treatment of coronary artery disease

BACKGROUND Cardiac shock wave therapy (CSWT) improves cardiac function in patients with severe coronary artery disease (CAD). We aimed to evaluate the clinical outcomes of a new CSWT treatment regimen. METHODS The 55 patients with severe CAD were randomly divided into 3 treatment groups. The control group (n = 14) received only medical therapy. In group A ( n = 20), CSWT was performed 3 times...

full text

Extracorporeal Shock Wave Therapy

When extracorporeal shock wave therapy (ESWT) was administered to the equine metacarpus/ metatarsus, there was subperiosteal and subendosteal hemorrhage, but no microfractures were detected. No damage to the surrounding soft tissues was detected. The principle of ESWT and the acute effects of ESWT on equine bone and soft tissue are explained. Authors’ Addresses: Department of Veterinary Clinica...

full text

Extracorporeal Shock Wave Therapy (eswt)

INSTRUCTIONS FOR USE This Medical Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the enrollee specific document must be referenced. The terms of an enrollee's document (e.g., Certificate of Coverage (COC) or Summary Plan Description (SPD) and Medicaid State Contracts) may differ greatly from the standard benefit plans upon which this Medical P...

full text

Extracorporeal Shock Wave Therapy (ESWT)

The services described in Oxford policies are subject to the terms, conditions and limitations of the Member's contract or certificate. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage enrollees. Oxford reserves the right, in its sole discretion, to modify policies as necessary without prior written notice unless otherwise required by Oxford's administrative procedure...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 6  issue 1

pages  1- 9

publication date 2018-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023